Subscribe To

Price Alert Latest News Economic Calendar News

TMO / Moderna and Thermo Fisher enter long-term agreement on large-scale manufacturing of COVID vaccine

Moderna Inc. MRNA, -0.53% and life-sciences company Thermo Fisher Scientific Inc. TMO, -1.35% said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the former's COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna's pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine. Read More

Demo Live Account See Partner Details

Content Topics

Dy

Corporation

013570

Ks

Moderna

Thermo

Fisher

Long term

Agreement

Large scale

Manufacturing

Vaccine

Stock

TMO

Posted: Feb 23 2022, 08:36

Author Name: Market Watch

TMO News

By Market Watch
October 25, 2023

Thermo Fisher's stock on track for lowest close in more than three years after revenue miss and lowered guidance

Thermo Fisher Scientific Inc.'s stock TMO, -7.80% fell about 9% Wednesday to put it on track for its lowest close in more than three years, after the

By Proactive Investors
October 25, 2023

Thermo Fisher lowers profit and sales outlook on soft demand, rising costs

Thermo Fisher Scientific (NYSE:TMO) issued a forecast for full-year profit and sales that falls below Wall Street expectations on lower-than-expected

By Zacks Investment Research
October 25, 2023

Thermo Fisher Scientific (TMO) Beats Q3 Earnings and Revenue Estimates

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.69 per share, beating the Zacks Consensus Estimate of $5.58 per share. This comp

By Barrons
October 25, 2023

Thermo Fisher Stock Slumps After Sales Miss and Outlook Is Slashed Again

The leading maker of scientific equipment slashes its guidance for the second consecutive quarter, citing a challenging macro environment.

By Reuters
October 25, 2023

Thermo Fisher cuts annual profit forecast on weak biotech demand

Medical equipment maker Thermo Fisher Scientific on Wednesday cut its annual profit forecast for the second straight quarter, hurt by lower-than-expec

By Proactive Investors
October 17, 2023

Olink Holding stock soars on acquisition by Thermo Fisher Scientific

Olink Holding AB shares surged 66% to $24.87 in late-morning trading on Tuesday after the provider of next-generation proteomics solutions announced t

By Barrons
October 17, 2023

Thermo Fisher to Buy Sweden's Olink for $3.1 Billion

Thermo Fisher will acquire proteomics company Olink for $26 per American depositary share in cash.

By Market Watch
October 17, 2023

Thermo Fisher's stock slips after deal to buy Sweden's Olink for a 74% premium

Thermo Fisher Scientific Inc. TMO, +1.18% announced Tuesday an agreement to buy Sweden-based proteomics company Olink Holding AB OLK, +0.47% in a deal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.